Self-Assembling Myristoylated Human Α-Defensin 5 As a Next-Generation Nanobiotics Potentiates Therapeutic Efficacy in Bacterial Infection.

Ruyi Lei,Jinchao Hou,Qixing Chen,Weirong Yuan,Baoli Cheng,Yaqi Sun,Yue Jin,Lujie Ge,Shmuel A. Ben-Sasson,Jiong Chen,Hangxiang Wang,Wuyuan Lu,Xiangming Fang
DOI: https://doi.org/10.1021/acsnano.7b09109
IF: 17.1
2018-01-01
ACS Nano
Abstract:The increasing prevalence of antibacterial resistance globally underscores the urgent need to the update of antibiotics. Here, we describe a strategy for inducing the self-assembly of a host-defense antimicrobial peptide (AMP) into nanoparticle antibiotics (termed nanobiotics) with significantly improved pharmacological properties. Our strategy involves the myristoylation of human α-defensin 5 (HD5) as a therapeutic target and subsequent self-assembly in aqueous media in the absence of exogenous excipients. Compared with its parent HD5, the C-terminally myristoylated HD5 (HD5-myr)-assembled nanobiotic exhibited significantly enhanced broad-spectrum bactericidal activity in vitro. Mechanistically, it selectively killed Escherichia coli ( E. coli) and methicillin-resistant Staphylococcus aureus (MRSA) through disruption of the cell wall and/or membrane structure. The in vivo results further demonstrated that the HD5-myr nanobiotic protected against skin infection by MRSA and rescued mice from E. coli-induced sepsis by lowering the systemic bacterial burden and alleviating organ damage. The self-assembled HD5-myr nanobiotic also showed negligible hemolytic activity and substantially low toxicity in animals. Our findings validate this design rationale as a simple yet versatile strategy for generating AMP-derived nanobiotics with excellent in vivo tolerability. This advancement will likely have a broad impact on antibiotic discovery and development efforts aimed at combating antibacterial resistance.
What problem does this paper attempt to address?